Spotlight -

Long-Acting Injectable Therapy in the Management of Adult Patients with Schizophrenia|

Major Depressive Disorder

News|Videos|May 15, 2023

Various Definitions of Treatment Resistant Depression

Author(s)Lisa Harding, MD

Don't miss this session at the APA 2023 Annual Meeting in San Francisco!

Lisa Harding, MD, shares a preview of her session, "Treatment Resistant Depression From Multiple Perspectives: Does It Exist?" for the APA 2023 Annual Meeting in San Francisco with Carl D. Marci, MD; Joseph Zabinski, PhD; and Steven P. Levine, MD.

Check out this session on Saturday, May 20 at 1:30-3:00PM PDT in Room 303, Moscone South.

Dr Harding is an board-certified psychiatrist and intervention specialist in Milford, CT.

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Related Content

anhedonia

Repurposing Dopamine Agonist Pramipexole for Disabling Anhedonia

ByKenneth J. Bender, PharmD, MA

September 3rd 2026

depressive disorder

Presenting Our September 2026 Theme: Depressive Disorders

September 1st 2026

depression

When Treatment-Resistant Depression Means Mismatched: Rethinking Difficult-to-Treat Depression

ByWalter Paganin, MD, PhD

August 31st 2026

Novel Serotonergic Agonist, HLP003, Targets the Adjunctive MDD Treatment Gap

Novel Serotonergic Agonist, HLP003, Targets the Adjunctive MDD Treatment Gap

ByKen Kramer, PhD

August 30th 2026

Debunking HRT Myths: Why Hormone Therapy Should Be Standard of Care in Psychiatry

ByNardin Valentin, DO

August 29th 2026

Latest CME

Jersey City Psychiatry

In-Person Event

Jersey City Psychiatry

October 2-3, 2026

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

John Koo, MD; T.J. Chao, MPAS, PA-C

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Ilan Melnick, MD; Linda Collado, MD, DABPN, FAPA; Maria Collado, MD, FAPA

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Juan D. Oms, MD, FAPA; Linda Collado, MD, DABPN, FAPA; Ginger Shupe, MD

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Patricia Junquera, MD; Maria Collado, MD; Erin C. Crown, MHSPAS, PA-C, Psych-CAQ

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Cases and Conversations™: Optimizing Administration of Treatment for Patients with Schizophrenia

Cases and Conversations™: Optimizing Administration of Treatment for Patients with Schizophrenia

Gus Alva, MD, DFAPA; Erin Crown, MHS, PA-C

Trending on Psychiatric Times

GLP-1 Receptor Agonists Linked to Lower Mortality, Cardiovascular Events in Serious Mental Illness

When Treatment-Resistant Depression Means Mismatched: Rethinking Difficult-to-Treat Depression

Repurposing Dopamine Agonist Pramipexole for Disabling Anhedonia

Ethics and AI Use in Medical Practice: American College of Physicians Releases Position Statement

Brain Trust: Anita H. Clayton, MD, on Diagnosing and Treating Sexual Dysfunction